ArticleCureus2026
Safety and Effectiveness of Insulin Degludec in Patients With Type 2 Diabetes Mellitus With Chronic Liver Disease.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Managing patients with type 2 diabetes mellitus (T2DM) with chronic liver disease (CLD) is challenging due to an increased risk of hypoglycemia. Among other long-acting basal insulin analogs, insulin degludec has been shown to have a low risk of hypoglycemic events in patients with T2DM. Aim To evaluate the effectiveness of insulin degludec in managing T2DM in patients with CLD based on changes in glycated hemoglobin (HbA1c), fasting plasma glucose, and postprandial glucose (PPG) levels, and to evaluate its safety, based on the incidence of hypoglycemic events. Methods This single-center, observational, retrospective study was conducted using data from 35 patients, aged between 18 and 75 years, with T2DM, a body mass index (BMI) of <40 kg/m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.